JP2018515605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515605A5 JP2018515605A5 JP2018510322A JP2018510322A JP2018515605A5 JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5 JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- composition
- subject
- ldl
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158157P | 2015-05-07 | 2015-05-07 | |
| US62/158,157 | 2015-05-07 | ||
| PCT/US2016/031109 WO2016179456A1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515605A JP2018515605A (ja) | 2018-06-14 |
| JP2018515605A5 true JP2018515605A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
| JP6751756B2 JP6751756B2 (ja) | 2020-09-09 |
Family
ID=57218627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510322A Expired - Fee Related JP6751756B2 (ja) | 2015-05-07 | 2016-05-06 | 低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用 |
Country Status (18)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249521A1 (zh) * | 2015-05-07 | 2018-11-02 | 肿瘤免疫股份有限公司 | Cd24用於降低低密度脂蛋白胆固醇水平的用途 |
| SG11201908077XA (en) * | 2017-03-07 | 2019-09-27 | Oncoimmune Inc | Methods of use of soluble cd24 for treating systemic lupus erythematosus |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| US20210046154A1 (en) * | 2018-03-05 | 2021-02-18 | Oncoimmune, Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| TW202015753A (zh) * | 2018-06-04 | 2020-05-01 | 美商昂科免疫公司 | 以cd24預防及治療移植物抗宿主病及黏膜炎之方法 |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| WO2020163529A1 (en) * | 2019-02-06 | 2020-08-13 | Oncoimmune, Inc. | Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis |
| US20220000974A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes |
| US20230103352A1 (en) * | 2020-02-10 | 2023-04-06 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating sars-cov-2 infection |
| EP4103217A4 (en) * | 2020-02-10 | 2024-03-13 | Oncoimmune Inc. | METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| WO2001072325A1 (en) * | 2000-03-29 | 2001-10-04 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| CN1323544A (zh) * | 2000-05-13 | 2001-11-28 | 蛋白质技术国际公司 | 降低低密度脂蛋白胆固醇浓度的组合物和方法 |
| JP2011509244A (ja) * | 2007-12-21 | 2011-03-24 | ユニバーシティー オブ ロチェスター | 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのcd24 |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| US8354520B2 (en) * | 2009-12-10 | 2013-01-15 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
| US20140357505A1 (en) * | 2011-06-10 | 2014-12-04 | The Trustees Of The University Of Pennsylvania | System And Method Of Cytomic Vascular Health Profiling |
| HK1249521A1 (zh) * | 2015-05-07 | 2018-11-02 | 肿瘤免疫股份有限公司 | Cd24用於降低低密度脂蛋白胆固醇水平的用途 |
-
2016
- 2016-05-06 HK HK18107984.3A patent/HK1249521A1/zh unknown
- 2016-05-06 ES ES16790128T patent/ES2829235T3/es active Active
- 2016-05-06 PT PT167901289T patent/PT3292144T/pt unknown
- 2016-05-06 HU HUE16790128A patent/HUE051866T2/hu unknown
- 2016-05-06 AU AU2016258084A patent/AU2016258084B2/en not_active Ceased
- 2016-05-06 CN CN201680026449.2A patent/CN107531772B/zh not_active Expired - Fee Related
- 2016-05-06 HR HRP20201651TT patent/HRP20201651T1/hr unknown
- 2016-05-06 MX MX2017014095A patent/MX385941B/es unknown
- 2016-05-06 CA CA2982612A patent/CA2982612A1/en not_active Abandoned
- 2016-05-06 JP JP2018510322A patent/JP6751756B2/ja not_active Expired - Fee Related
- 2016-05-06 US US15/572,330 patent/US10369197B2/en not_active Expired - Fee Related
- 2016-05-06 EA EA201792418A patent/EA038520B1/ru unknown
- 2016-05-06 EP EP16790128.9A patent/EP3292144B1/en not_active Not-in-force
- 2016-05-06 KR KR1020177032235A patent/KR20170141216A/ko not_active Ceased
- 2016-05-06 BR BR112017022394A patent/BR112017022394A2/pt not_active IP Right Cessation
- 2016-05-06 WO PCT/US2016/031109 patent/WO2016179456A1/en not_active Ceased
-
2017
- 2017-10-10 ZA ZA2017/06846A patent/ZA201706846B/en unknown
- 2017-10-17 IL IL255086A patent/IL255086B/en unknown
-
2019
- 2019-06-17 US US16/443,498 patent/US11026995B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7166478B2 (ja) | ヒトヒアルロニダーゼph20の変異体及び薬物を含む皮下投与用医薬組成物 | |
| Lei et al. | Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig | |
| Deng et al. | Nav1. 7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids | |
| Veritti et al. | Neovascular age-related macular degeneration | |
| Schellekens | Factors influencing the immunogenicity of therapeutic proteins | |
| US7303748B2 (en) | Method of treating eye injury with local administration of a VEGF inhibitor | |
| Palmer et al. | Liddle’s syndrome | |
| Matsuka et al. | Factor XIIIa-catalyzed cross-linking of recombinant αC fragments of human fibrinogen | |
| Mancuso et al. | Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias | |
| Morar-Mitrica et al. | Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration | |
| Hermans et al. | Recombinant factor VIII Fc for the treatment of haemophilia A | |
| JP2018528237A (ja) | 治療剤に対する免疫応答を除去するための改善された方法及び化合物 | |
| Richter et al. | Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice | |
| CN107531772A (zh) | Cd24用于降低低密度脂蛋白胆固醇水平的用途 | |
| Sun et al. | Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies | |
| Sankar et al. | The evolution of recombinant factor replacement for hemophilia | |
| JP2016530284A (ja) | 疾患及び障害を治療するためにインターロイキン−10を使用する方法 | |
| Jiang et al. | 2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders | |
| Valentino et al. | The biological efficacy profile of BAX 855, a PEG ylated recombinant factor VIII molecule | |
| Garger et al. | BAY 81‐8973, a full‐length recombinant factor VIII: manufacturing processes and product characteristics | |
| Santagostino | A new recombinant factor VIII: from genetics to clinical use | |
| Chintalgattu et al. | Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model | |
| Akhtar et al. | Molecular basis of proteinuria | |
| JP2019506408A5 (cg-RX-API-DMAC7.html) | ||
| Ijima et al. | Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis |